Let's be completely clear about 2026: The era of easy money is dead, and companies are scrambling. If you aren't making actual cash, you are busy performing financial gymnastics to stay relevant.

Take Innoviz Technologies (INVZ.US). They finally pulled in a record $18.1 million in Q2 and are pivoting hard into defense applications. Because if automakers won't buy your LiDAR systems fast enough, perhaps the military will pay you for drone detection. It is a cynical but necessary survival move.

Then we have the identity verification players. Mitek Systems (MITK.US) is actually making money—a rare feat—posting $54 million in Q3 by fighting the deepfake nightmare that generative AI has unleashed upon us all. They are solving a real mess and getting paid for it.

Over in biotech, it is an absolute bloodbath of corporate maneuvering. Longeveron (LGVN.US) and Zhongchao (ZCMD.US) are both playing the reverse stock split game just to avoid getting kicked off the Nasdaq. It is a sad look. Meanwhile, Kura Oncology (KURA.US) decided to spin off its diabetes research into a new entity just to keep its oncology narrative clean, while GRI Bio (GRI.US) is desperately touting its Phase 2a fibrosis data to anyone who will listen. Biomerica (BMRA.US) isn't faring much better, scraping by with private placements and Saudi diagnostic approvals.

And what about the old-school economy? CF Industries (CF.US) is raking in cash from ammonia and hiking its dividend by 20%. Analysts might be whining about future supply gluts, but right now, fertilizer is paying out significantly better than half the speculative tech sector.

Toss in the stragglers like CV (CV.US) and SKHQ (SKHQ.US), and you have a market where everyone is just trying to keep their heads above water in an unforgiving macroeconomic reality.